TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15920184
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 1.0 mg/kg (D 1)
Study: 14519792
Drug: Sterol ester
Normalized name: lanosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol ester group (n = 28) consuming croissants and magdalenas enriched with sterol esters (3.2 g/d) for 8 weeks
Study: 8793613
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg promethazine
Study: 11051308
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg promethazine
Study: 1418048
Drug: Terfenadine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (oral therapeutic doses)
Study: 6747018
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 to 2000 mg/day)
Study: 6747018
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 320 mg/day)
Study: 26614889
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy with the Rezūm® System
Study: 25440375
Drug: Curcuminoids (C3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (C3 complex®); 1000 mg/day; n=50
Study: 17432676
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (group A)
Study: 17432676
Drug: Integrated Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese and Western medicine (group B)
Study: 11916918
Drug: Blood letting
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood letting (three phlebotomies of 500 ml at 2-week intervals)
Study: 10972349
Drug: Mineral supplementation
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral supplementation and vitamin D dose of 1000 IU/day
Study: 10972349
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of vitamin D (500 IU/day)
Study: 9365972
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg.kg‐1
Study: 1540020
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with RA not receiving drugs or receiving only NSAIDs
Study: 1540020
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with RA receiving second line treatment in addition to NSAIDs
Study: 3548209
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (Group A)
Study: 3548209
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 as a vaginal suppository (Group B)
Study: 19875087
Drug: Pegaptanib 0.3
Normalized name: PEGAPTANIB 0.3MG/0.09ML INTRAOCULAR SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaptanib 0.3 mg
Study: 19875087
Drug: Pegaptanib 1
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib 1 mg
Study: 11939381
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support from the community drug team (CDT)
Study: 10516703
Drug: Atovaquone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (1500 mg daily from transplant day -5 to day -1, then 3 days per week until day +100)
Study: 10516703
Drug: TMP/SMX (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX (160/800 mg daily from transplant day -5 to day -1, then 3 days per week until day +100)
Study: 7726804
Drug: Behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural group treatment
Study: 2402122
Drug: 5% NaCl
Normalized name: LVP solution Dextrose 5% with 0.45% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaCl infusion (6 mEq per kg body wt for 120 minutes)
Study: 2402122
Drug: 2.5% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% NaCl infusion (6 mEq per kg body wt for 120 minutes)
Study: 2402122
Drug: 5% NaCl
Normalized name: LVP solution Dextrose 5% with 0.45% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaCl infusion
Study: 2402122
Drug: Desoxycorticosterone acetate
Normalized name: desoxycorticosterone acetate
DrugBank: Desoxycorticosterone acetate (DB06780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoxycorticosterone acetate (DOCA; 20 mg i.m. for three days) before saline (5%) infusion
Study: 31997794
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma therapy with total contact casting (Group A)
Study: 30940833
Drug: FOS at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS at 2.5 g/day
Study: 30940833
Drug: FOS at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS at 5 g/day
Study: 30940833
Drug: FOS at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS at 10 g/day
Study: 30940833
Drug: Placebo (Maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Maltodextrin 10 g/day)
Study: 30940833
Drug: FOS (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS (all doses)
Study: 27910708
Drug: Myo-inositol (2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g twice a day)
Study: 27910708
Drug: Myo-inositol (2 g/d)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol (2 g/d) plus melatonin (3 g/d before sleeping)
Study: 22448804
Drug: Adjunctive emotion
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive emotion regulation group therapy (ERGT) for 14 weeks
Study: 17206289
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml normal saline infused before and during cardiopulmonary bypass)
Study: 11555157
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with levamisole plus Chinese medicinal herbs
Study: 7923458
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 to 90 mg/day
Study: 7923458
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 to 2000 mg/day
Study: 30130297
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with information that it would reduce pain
Study: 30130297
Drug: Natural history
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural history group receiving pain stimuli without any application of cream or manipulation of expectation
Study: 23553549
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion 150 mEq/L in 5% dextrose solution
Study: 23553549
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride 154 mEq/L infusion
Study: 29910040
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion
Study: 23553549
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion
Study: 20090541
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg(‐1) hydroxyzine hydrochloride suspension (Atarax) 1 h preoperatively (group I, n=15)
Study: 20090541
Drug: 0.7 mg
Normalized name: naloxone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg kg(‐1) midazolam (Dormicum) 15 min preoperatively (group II, n=15)
Study: 20090541
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg kg(‐1) ketamine (Ketalar) with 0.25 mg kg(‐1) midazolam (Dormicum) 15 min preoperatively (group III, n=15)
Study: 20090541
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral premedication administration (group IV, controls, n=15)
Study: 17180512
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) with weekly carboplatin or low daily dose of cisplatin
Study: 14649345
Drug: Adenosine 80
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 80 microg kg min infusion
Study: 14649345
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) infusion
Study: 6487508
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (conventional therapeutic doses)
Study: 25198487
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music therapy (Control)
Study: 27442130
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac
Study: 12459926
Drug: Risperidone 0.25
Normalized name: risperidone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.25 mg
Study: 12459926
Drug: Risperidone 0.5
Normalized name: risperidone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5 mg
Study: 10514777
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 20 mg of lidocaine
Study: 10514777
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 40 mg of lidocaine
Study: 1932611
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5 mg benzydamine
Study: 1932611
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of benzydamine
Study: 1932611
Drug: Dermal cream
Normalized name: PLO Transdermal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal cream application of benzydamine
Study: 6588267
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (3 to 5 times weekly for a mean of 12 +/- 4 months)
Study: 29231343
Drug: Nilestriol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilestriol (1 mg once a day) combined with oryzanol (20 mg three times per day)
Study: 24169335
Drug: Glycyrrhizin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (25 mg/kg)
Study: 24169335
Drug: Glycyrrhizin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (50 mg/kg)
Study: 24169335
Drug: Glycyrrhizin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (75 mg/kg)
Study: 24169335
Drug: IL‐13 control
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐13 control (10 µg/L IL‐13 + physiological saline)
Study: 24169335
Drug: Glycyrrhizin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (25 µmol/L)
Study: 24169335
Drug: Glycyrrhizin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (50 µmol/L)
Study: 24169335
Drug: Glycyrrhizin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (75 µmol/L)
Study: 18653640
Drug: Measles vaccination
Normalized name: Measles vaccine (live)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccination using standard titre Edmonston‐Zagreb vaccine at 4.5 months of age
Study: 18653640
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (vaccinated)
Study: 16868892
Drug: 1.5 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 or 3.0 mg dexamethasone (DEX) per os at 09:00 or 21:00 hours
Study: 9150772
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of fentanyl (2 micrograms/ml) and bupivacaine (1.0 mg/ml) at a rate of 0.25 ml.kg‐1.h‐1
Study: 9150772
Drug: Intermittent epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent epidural morphine (30 micrograms/kg every 8 h)
Study: 7957516
Drug: Sublingual spray
Normalized name: Myoden, sublingual spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray (2.5 mg)
Study: 7957516
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet (5 mg)
Study: 7957516
Drug: Peroral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral tablet (10 mg)
Study: 21457065
Drug: Pioglitazone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone + Metformin (PM)
Study: 21457065
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Glimepiride (GM)
Study: 18339222
Drug: DHA-rich tuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich tuna fish oil (6 g fish oil/d, DHA 1.56 g/d, EPA 0.36 g/d)
Study: 16545929
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO(4)) 250 mg/kg intravenous solution
Study: 11094664
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg intravenously
Study: 26597577
Drug: No cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cold therapy
Study: 29564722
Drug: Pixantrone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone monotherapy
Study: 17152731
Drug: Thymomimetic Vilon
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymomimetic Vilon (Lys‐Glu) administration
Study: 17152731
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for DM‐1 patients
Study: 14974912
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg intramuscularly) plus tibolone (2.5 mg/day)
Study: 14974912
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg intramuscularly) plus placebo
Study: 8706769
Drug: Levosimendan 1
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 1 mg
Study: 8907133
Drug: Levosimendan 2
Normalized name: levosimendan 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 2 mg
Study: 8706769
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg b.i.d.) with levosimendan
Study: 3980061
Drug: L-dopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (125 mg)
Study: 3980061
Drug: L-dopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (125 mg) plus carbidopa (12.5 mg)
Study: 3980061
Drug: Tyrosine load
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine load (100 mg/kg)
Study: 31426299
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum HEAL9 and L. paracasei 8700:2 (probiotic group)
Study: 26602073
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg plus Ezetimibe 10 mg
Study: 19797013
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.1 mg triptorelin administered on day 3 after embryo transfer)
Study: 17026560
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection with detachable snare (group A)
Study: 17026560
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection alone (group B)
Study: 12777340
Drug: Tapering off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering off plus group CBT
Study: 12777340
Drug: Tapering off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering off alone
Study: 9378207
Drug: Pancreatic duct
Normalized name: Sus scrofa bile duct preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic duct injections (10 or more injections) in Group I
Study: 3872304
Drug: Papaverine hydrochloride
Normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine hydrochloride (1 mg in 10 cc normal saline)
Study: 3872304
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 cc normal saline)
Study: 16956818
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid iv every 6 months (group A)
Study: 16956818
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid iv every 3 months (group B)
Study: 10551639
Drug: Donor-specific transfusion
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-specific transfusion (DST) administered 24 hr before transplant and 7-10 days posttransplant
Study: 25582800
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy for children (MBCT-C)
Study: 24670086
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) (50,000 IU lipase)
Study: 11882513
Drug: Low-dose glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose glucose infusion at a mean rate of 6 mg x kg(‐1) x min(‐1)
Study: 11882513
Drug: High-dose glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucose infusion at a mean rate of 12 mg x kg(‐1) x min(‐1)
Study: 9878012
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg famciclovir
Study: 6795656
Drug: Maprotiline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (up to 150 mg/day for 2 weeks, then up to 300 mg/day if indicated)
Study: 22803597
Drug: Atomoxetine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 20 mg twice daily
Study: 22803597
Drug: Atomoxetine 60
Normalized name: atomoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 60 mg twice daily
Study: 21363899
Drug: Conventional ward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ward treatment
Study: 17543656
Drug: RSI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSI plus etomidate bolus followed by continuous sedative infusion (ETO group)
Study: 17543656
Drug: RSI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSI plus placebo followed by continuous sedative infusion (placebo group)
Study: 12737240
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture supported by two endosseous implants with a connecting bar
Study: 10927737
Drug: Cocoa-bran cereal
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-bran cereal (25.0 g/d of total dietary fiber)
Study: 10927737
Drug: Low-fiber cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber cereal (5.6 g/d of total dietary fiber)
Study: 17822463
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg)
Study: 8723472
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg), Trimethoprim (200 mg), Dapsone (100 mg)
Study: 1328362
Drug: Low-dose angiotensin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose angiotensin II infusion
Study: 2865712
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dipipanone
Study: 2865712
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dipipanone
Study: 2865712
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dipipanone
Study: 3312977
Drug: Dihydroergotamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (0.5 mL, 1 mg/mL)
Study: 31736068
Drug: AS04‐HPV‐16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04‐HPV‐16/18 vaccine (in Arms A and B)
Study: 31736068
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (in Arms A/B and all Arm C)
Study: 12667722
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual 4mg
Study: 11082801
Drug: 8-week nurse-managed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week nurse-managed, peer-led smoking cessation intervention including 21 mg nicotine patch therapy for 6 weeks, weekly counseling, and skills training
Study: 29680812
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application used weekly for 12 months
Study: 29680812
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care involving regular (approximately 3 monthly) CF outpatient clinic appointments
Study: 30634207
Drug: Jiedu Shengji
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiedu Shengji Recipe (JSR), one dose per day for 8 weeks
Study: 30634207
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: mixture of dexamethasone, lidocaine, and gentamicin, 10 mL each time before radiation
Study: 23519913
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride (APF) gel for 4 min
Study: 23519913
Drug: Fractional CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO(2) laser applied before APF gel (10 mJ, 200 Hz, 10 s)
Study: 23519913
Drug: Fractional CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO(2) laser applied through APF gel (10 mJ, 200 Hz, 10 s)
Study: 22372591
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 40 mg every second day